GSK Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 5.1% compared to GSK PLC's net margin of 21.81%. GSK PLC's return on equity of 19.22% beat BioNTech SE's return on equity of -3.39%.

GSK PLC has a consensus price target of $43.42, signalling upside risk potential of 9.96%. On the other hand BioNTech SE has an analysts' consensus of $139.99 which suggests that it could grow by 40.73%. Given that BioNTech SE has higher upside potential than GSK PLC, analysts believe BioNTech SE is more attractive than GSK PLC.

GSK PLC has a beta of 0.601, which suggesting that the stock is 39.914% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.756%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 3.94%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than BioNTech SE quarterly revenues of $1.3B. GSK PLC's net income of $530.1M is higher than BioNTech SE's net income of $276.6M. Notably, GSK PLC's price-to-earnings ratio is 24.94x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 2.04x versus 8.03x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 5.1% compared to GSK PLC's net margin of 15.24%. GSK PLC's return on equity of 19.22% beat Johnson & Johnson's return on equity of 19.98%.

GSK PLC has a consensus price target of $43.42, signalling upside risk potential of 9.96%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that GSK PLC has higher upside potential than Johnson & Johnson, analysts believe GSK PLC is more attractive than Johnson & Johnson.

GSK PLC has a beta of 0.601, which suggesting that the stock is 39.914% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 3.94%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. GSK PLC pays 94.91% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. GSK PLC's net income of $530.1M is lower than Johnson & Johnson's net income of $3.4B. Notably, GSK PLC's price-to-earnings ratio is 24.94x while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 2.04x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 5.1% compared to GSK PLC's net margin of -117.16%. GSK PLC's return on equity of 19.22% beat Moderna's return on equity of -29.09%.

GSK PLC has a consensus price target of $43.42, signalling upside risk potential of 9.96%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than GSK PLC, analysts believe Moderna is more attractive than GSK PLC.

GSK PLC has a beta of 0.601, which suggesting that the stock is 39.914% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 3.94%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Moderna quarterly revenues of $956M. GSK PLC's net income of $530.1M is higher than Moderna's net income of -$1.1B. Notably, GSK PLC's price-to-earnings ratio is 24.94x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 2.04x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of 5.1% compared to GSK PLC's net margin of 6.54%. GSK PLC's return on equity of 19.22% beat Sanofi SA's return on equity of 7.55%.

GSK PLC has a consensus price target of $43.42, signalling upside risk potential of 9.96%. On the other hand Sanofi SA has an analysts' consensus of $63.58 which suggests that it could grow by 10.1%. Given that Sanofi SA has higher upside potential than GSK PLC, analysts believe Sanofi SA is more attractive than GSK PLC.

GSK PLC has a beta of 0.601, which suggesting that the stock is 39.914% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.401%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 3.94%. Sanofi SA offers a yield of 6.82% to investors and pays a quarterly dividend of $2.04 per share. GSK PLC pays 94.91% of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Sanofi SA quarterly revenues of $8.1B. GSK PLC's net income of $530.1M is lower than Sanofi SA's net income of $531.9M. Notably, GSK PLC's price-to-earnings ratio is 24.94x while Sanofi SA's PE ratio is 23.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 2.04x versus 3.01x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.